Navigation Links
Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
Date:11/11/2008

ay significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission ("SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; and our annual report on Form 10-K filed with the SEC on October 30, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

T
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
2. Raptor Pharmaceuticals Provides Update on Targeting Platforms
3. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
4. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
8. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
9. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
10. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
11. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
(Date:1/14/2014)... January 14, 2014 Equashield ( ... hazardous drugs, today announced that it has achieved ... year.   Equashield,s closed systems reduce ... nurses and other medical professionals who prepare and ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... consumer protection program provided by the National Association of ... on quality of care when buying medications online. Similarly, ... "know your medicine, know your pharmacist," highlights the pharmacist,s ... The AWARxE program aims to educate patients on the ...
... VIEW, Calif., Oct. 12 Based on its ... & Sullivan presents Xenemetrix, Inc. with the 2010 ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) ... leading designer, manufacturer, and distributor of Energy Dispersive ...
Cached Medicine Technology:AWARxE Recognizes American Pharmacists Month 2Frost & Sullivan Global Product Line Strategy of the Year Award Presented to Xenemetrix 2Frost & Sullivan Global Product Line Strategy of the Year Award Presented to Xenemetrix 3
(Date:4/24/2014)... Changes in managing patients before, during and after ... reduced readmission rates, according to researchers who led a ... The practice, called enhanced recovery, is easier on patients ... bowel evacuation that are typically prescribed. After surgery, patients ... as possible, leading to faster recoveries. , Among findings ...
(Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
(Date:4/24/2014)... was the first in the world to discover a ... the jaw. , Ameloblastoma is an odontogenic tumour with ... most often found in the posterior of the lower ... tissue deficiencies in the jaws as well as loss ... the need for surgery and the recurrence of ameloblastoma, ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
(Date:4/23/2014)... Pregnant immigrants from Sub-Saharan Africa, Latin America and ... according to new research from St. Michael,s Hospital. ... British Journal of Obstetrics and Gynaecology , assessed ... immigrants and native-born women in six high-immigration countries ... (Catalonia and Valencia) and the United States (California, ...
Breaking Medicine News(10 mins):Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2
... seniors , , DETROIT, Dec. ... and chiropractic services to its Flexible Health Options Benefit for ... list of services to promote wellness encourages Medicare beneficiaries to ... in their wallets. , , ...
... Seele,Founder/CEO of The Balm In Gilead, joined Rick Warren, pastor ... community leaders at a,Civic Forum on Global Health for a ... Lady Laura Bush,s leadership in addressing,HIV around the globe. , ... first State of the Union address that President Bush pledged,to ...
... center focused,on improving the quality of life of children ... led by a world-renowned researcher whose,concepts and tools are ... The Siskin Center for Child and Family Research joins ... organization focused,on education, outreach and support for children with ...
... 3, 2008 Joined by actress Maggie,Gyllenhaal, Duracell(R) today announced the ... in age from six to 15 years old --,at an event ... best known for her role in "The Dark Knight," to promote ... of powering,up a gift for the first time to those most ...
... WALTHAM, Mass., Dec. 3 Decision Resources, one ... on pharmaceutical and,healthcare issues, finds that the diagnosis ... extremely low and will remain low through 2012,particularly ... disease,will account for approximately 70 percent of the ...
... sense approach to dieting. , ... San Francisco, CA ... source for comparing the most valuable Internet services, is launching ... a free guide filled with useful advice for those embarking on ...
Cached Medicine News:Health News:UPDATE: HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 2Health News:UPDATE: HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 3Health News:The Balm In Gilead Joins Saddleback Church in Thanking President Bush for His Leadership on Addressing HIV and AIDS Around the World 2Health News:Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education 2Health News:Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education 3Health News:Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education 4Health News:Duracell and Actress Maggie Gyllenhaal Announce Winners of 'Power A Smile' Casting Call After Nationwide Search for Five Child Holiday Ambassadors 2Health News:Duracell and Actress Maggie Gyllenhaal Announce Winners of 'Power A Smile' Casting Call After Nationwide Search for Five Child Holiday Ambassadors 3Health News:Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Through 2012 2Health News:Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Through 2012 3Health News:NextAdvisor.com Launches "Lose the Weight this Year: A Common Sense Dieter's Guide" 2
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
IOL explanation snare for foldable lenses. Snare bisects lens for easy removal. Easy thumb activation. Replacement snares available E3526....
Medicine Products: